Edwards Lifesciences Corp (EW) stock
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$105.43−1.68 (-1.57%)
Close on Nov 17, 2026Market cap $60.77BP/E 60.6Yield –
Edwards Lifesciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Edwards Lifesciences's operating income for the twelve months ending Jun 30, 2026 was $1.45B, down 1.4% year over year. For fiscal 2025 it was $1.26B, down 8.3% from the year before. The highest annual figure on record is $1.69B in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | -8.3% |
| FY2024 | Dec 31, 2024 | $1.38B | +5.3% |
| FY2023 | Dec 31, 2023 | $1.31B | -12.6% |
| FY2022 | Dec 31, 2022 | $1.50B | -11.4% |
| FY2021 | Dec 31, 2021 | $1.69B | +88.3% |
| FY2020 | Dec 31, 2020 | $897.60M | -21.7% |
| FY2019 | Dec 31, 2019 | $1.15B | +53.3% |
| FY2018 | Dec 31, 2018 | $748.20M | -31.3% |
| FY2017 | Dec 31, 2017 | $1.09B | +45.0% |
| FY2016 | Dec 31, 2016 | $751.20M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $513.20M | +24.8% |
| Q1 FY2026 | Mar 31, 2026 | $477.60M | +21.0% |
| Q4 FY2025 | Dec 31, 2025 | $151.10M | -51.7% |
| Q3 FY2025 | Sep 30, 2025 | $307.10M | -12.4% |
| Q2 FY2025 | Jun 30, 2025 | $411.20M | +12.2% |
| Q1 FY2025 | Mar 31, 2025 | $394.80M | +13.1% |
| Q4 FY2024 | Dec 31, 2024 | $312.60M | -9.9% |
| Q3 FY2024 | Sep 30, 2024 | $350.60M | -4.2% |
| Q2 FY2024 | Jun 30, 2024 | $366.50M | +39.1% |
| Q1 FY2024 | Mar 31, 2024 | $349.00M | -10.1% |
| Q4 FY2023 | Dec 31, 2023 | $346.80M | +75.4% |
| Q3 FY2023 | Sep 30, 2023 | $365.90M | -9.1% |
| Q2 FY2023 | Jun 30, 2023 | $263.50M | -42.7% |
| Q1 FY2023 | Mar 31, 2023 | $388.40M | -11.5% |
| Q4 FY2022 | Dec 31, 2022 | $197.70M | -47.2% |
| Q3 FY2022 | Sep 30, 2022 | $402.40M | +3.1% |
| Q2 FY2022 | Jun 30, 2022 | $459.50M | -15.2% |
| Q1 FY2022 | Mar 31, 2022 | $438.80M | +14.4% |
| Q4 FY2021 | Dec 31, 2021 | $374.40M | +6.5% |
| Q3 FY2021 | Sep 30, 2021 | $390.30M | +9.1% |
| Q2 FY2021 | Jun 30, 2021 | $542.10M | – |
| Q1 FY2021 | Mar 31, 2021 | $383.50M | +7.1% |
| Q4 FY2020 | Dec 31, 2020 | $351.40M | +13.1% |
| Q3 FY2020 | Sep 30, 2020 | $357.80M | +21.6% |
| Q2 FY2020 | Jun 30, 2020 | -$169.70M | -163.4% |
| Q1 FY2020 | Mar 31, 2020 | $358.10M | +30.6% |
| Q4 FY2019 | Dec 31, 2019 | $310.80M | – |
| Q3 FY2019 | Sep 30, 2019 | $294.30M | +18.2% |
| Q2 FY2019 | Jun 30, 2019 | $267.50M | +6.1% |
| Q1 FY2019 | Mar 31, 2019 | $274.20M | +8.6% |
| Q4 FY2018 | Dec 31, 2018 | -$5.30M | -101.6% |
| Q3 FY2018 | Sep 30, 2018 | $248.90M | +16.3% |
| Q2 FY2018 | Jun 30, 2018 | $252.10M | +4.6% |
| Q1 FY2018 | Mar 31, 2018 | $252.50M | -15.4% |
| Q4 FY2017 | Dec 31, 2017 | $336.10M | – |
| Q3 FY2017 | Sep 30, 2017 | $214.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $241.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $298.30M | – |
See a number that looks wrong?